Project B Taps Fashion Industry Veteran William Kim as Chief Lifestyle Officer February 23, 2026 Global basketball platform merges elite sport with fashion, design, and culture
BSE (formerly Bombay Stock Exchange) Selects ITRS to Strengthen Real-Time Monitoring and Operational Resilience February 23, 2026 Asia’s Oldest Stock Exchange Partners with ITRS to Strengthen Monitoring and Compliance
Danube Properties Launches Exclusive 0.5% Monthly Payment Plan As A Special Ramadan Offer February 23, 2026 In celebration of the holy month of Ramadan, Danube Properties has unveiled an exclusive 0.5% per month payment plan, reaffirming its commitment to making homeownership in Dubai more accessible while embracing the spirit of community and generosity that defines this auspicious season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219686823/en/ Designed to [...]
Ares Management Prices European Direct Lending CLO II at Over €300 Million February 23, 2026 Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely [...]
Compass Pathways Announces Pricing of $150 Million Public Offering February 23, 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants [...]
Synthetik Selected to Support Amentum-Led Team Hypersonics (UK) Industry Mission Partner February 23, 2026 Synthetik will deliver hypersonic modelling, environmental modelling and digital integration support, helping create knowledge hubs that accelerate a sovereign UK capability through collaboration with Government, academia, primes and SMEs.
TNS Launches TNSPay SmartRoute to Put Merchants and Acquirers in Control of Payment Routing February 23, 2026 New intelligent routing gives payments teams the power to set the rules, automate failover and keep revenue flowing – backed by global scale and enterprise-grade security.
Everbridge xMatters to Host London Event on the Future of Incident Management February 23, 2026 Everbridge, Inc., the global leader in High Velocity Critical Event Management (CEM) and national public warning solutions, will host an exclusive customer event on March 17 at the Churchill War Rooms in London, bringing together IT, DevOps, and operational leaders to discuss the evolving demands of modern incident management and operational resilience. This press release [...]
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
CBRE IM Backs IPUT Real Estate Dublin with Significant Equity Commitment February 23, 2026 - CBRE IM to increase investment in IPUT by €175m - Capital will kick-start a €500m IPUT Real Estate’s office investment programme - IPUT Real Estate is a market leader with a €2.7bn portfolio